Food and Drug Administration
Cardiovascular and Renal Drugs Advisory Committee
January 17, 2002
Slides
Avapro® (Irbesartan) in Type 2 Diabetic Renal Disease
Disclaimer
The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
Avapro® (Irbesartan) in Type 2 Diabetic Renal Disease, Introduction, Brian F Daniels, MD, Pharmaceutical Research Institute, Bristol-Myers Squibb pdf
Disease Background, Edmund J Lewis, MD, Muehrcke Professor of Nephrology and Director of the Section of Nephrology, Rush Medical College pdf
IDNT Irbesartan Diabetic Nephropathy Trial, Melissa Cooper, MD, MS, Pharmaceutical Research Institute, Bristol-Myers Squibb pdf
IRMA2 IRbesartan MicroAlbuminuria in Type 2 Diabetic Subjects, Hans-Henrik Parving, MD, DMSc, Professor and Chief Physician, Steno Diabetes Center pdf
Benefit: Risk Assessment, Edmund J Lewis, MD, Muehrcke Professor of Nephrology and Director of the Section of Nephrology, Rush Medical College pdf